Fatal Pulmonary Mycobacterium Celatum Infection in an Immunocompetent Patient.An Eight-Year Follow-Up of the First Case,a Review of the Literature and a Report of Beta-2 Microglobulin as a Potential Indicator of Disease Severity  

作　　者：S.Rustscheff J.Darelid 

机构地区：[1]Department of Internal Medicine,Varnamo General hospital and Department of Infectious diseases,Ryhov County hospital,Jonkoping,Sweden.

出　　处：《Advances in Infectious Diseases》2013年第4期253-256,共4页传染病进展（英文）

摘　　要：Setting: Swedish county hospital. Objective: Pulmonary M. celatum infection has been previously described only twice in an immunocompetent individual with no pre-existing chest disease. We describe the first Swedish case report of unusual drug-related complications and review the literature. Discussion: Atypical mycobacteriosis is often difficult to treat. We describe a fatal case of m celatum pneumonia in a previously healthy patient, unusual side effects encountered during her treatment and also the report of the utility of beta-2-microglobulin as a way to measure disease activity in mycobacterial infections. Conclusions: M. celatum may cause fatal pneumonia in previously healthy individuals. Treating the disease may be fraught with difficulty and there is a risk for very severe side effects, all of which must be weighed before taking the decision to treat this disease.Setting: Swedish county hospital. Objective: Pulmonary M. celatum infection has been previously described only twice in an immunocompetent individual with no pre-existing chest disease. We describe the first Swedish case report of unusual drug-related complications and review the literature. Discussion: Atypical mycobacteriosis is often difficult to treat. We describe a fatal case of m celatum pneumonia in a previously healthy patient, unusual side effects encountered during her treatment and also the report of the utility of beta-2-microglobulin as a way to measure disease activity in mycobacterial infections. Conclusions: M. celatum may cause fatal pneumonia in previously healthy individuals. Treating the disease may be fraught with difficulty and there is a risk for very severe side effects, all of which must be weighed before taking the decision to treat this disease.

关 键 词：Mycobacterium Celatum Immunocompenent 

分 类 号：R5[医药卫生—内科学]